CRDF vs. VSTM

Last updated Apr 1, 2026

Compare and contrast key facts about Cardiff Oncology, Inc. (CRDF) and Verastem, Inc. (VSTM).

Performance

CRDF vs. VSTM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Cardiff Oncology, Inc. (CRDF) and Verastem, Inc. (VSTM). The values are adjusted to include any dividend payments, if applicable.

CRDF vs. VSTM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CRDF Cardiff Oncology, Inc.	-42.35%	-35.25%	193.24%	5.71%	-76.71%	-66.59%	1,350.81%	-60.67%	-85.76%	-85.36%
VSTM Verastem, Inc.	-31.35%	49.32%	-36.49%	68.53%	-80.37%	-3.76%	58.96%	-60.12%	9.45%	174.11%

Fundamentals

EPS CRDF : -$0.69 VSTM : -$3.28
PS Ratio CRDF : 235.58 VSTM : 29.15
Total Revenue (TTM) CRDF : $459.00K VSTM : $13.38M
Gross Profit (TTM) CRDF : -$11.12M VSTM : $11.26M
EBITDA (TTM) CRDF : -$47.20M VSTM : -$238.93M

Returns By Period

In the year-to-date period, CRDF achieves a -42.35% return, which is significantly lower than VSTM's -31.35% return. Over the past 10 years, CRDF has underperformed VSTM with an annualized return of -41.52%, while VSTM has yielded a comparatively higher -11.97% annualized return.

CRDF

• 1D: 4.52%
• 1M: -16.49%
• YTD: -42.35%
• 6M: -21.36%
• 1Y: -48.41%
• 3Y*: -0.61%
• 5Y*: -30.00%
• 10Y*: -41.52%

VSTM

• 1D: 9.28%
• 1M: -7.34%
• YTD: -31.35%
• 6M: -39.98%
• 1Y: -12.11%
• 3Y*: 2.08%
• 5Y*: -30.06%
• 10Y*: -11.97%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CRDF vs. VSTM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRDF

CRDF Risk / Return Rank: 18
CRDF Sharpe Ratio Rank: 16
CRDF Sortino Ratio Rank: 20
CRDF Omega Ratio Rank: 20
CRDF Calmar Ratio Rank: 14
CRDF Martin Ratio Rank: 19

VSTM

VSTM Risk / Return Rank: 36
VSTM Sharpe Ratio Rank: 35
VSTM Sortino Ratio Rank: 40
VSTM Omega Ratio Rank: 39
VSTM Calmar Ratio Rank: 33
VSTM Martin Ratio Rank: 34

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRDF vs. VSTM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Cardiff Oncology, Inc. (CRDF) and Verastem, Inc. (VSTM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CRDF	VSTM	Difference
Sharpe ratio Return per unit of total volatility	-0.58	-0.14	-0.44
Sortino ratio Return per unit of downside risk	-0.46	0.41	-0.87
Omega ratio Gain probability vs. loss probability	0.94	1.05	-0.11
Calmar ratio Return relative to maximum drawdown	-0.76	-0.26	-0.50
Martin ratio Return relative to average drawdown	-1.19	-0.49	-0.69
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CRDF vs. VSTM - Sharpe Ratio Comparison

The current CRDF Sharpe Ratio is -0.58, which is lower than the VSTM Sharpe Ratio of -0.14. The chart below compares the historical Sharpe Ratios of CRDF and VSTM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CRDF	VSTM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.58	-0.14	-0.44
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.30	-0.29	-0.02
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.39	-0.12	-0.27
Sharpe Ratio (All Time) Calculated using the full available price history	-0.23	-0.23	0.00

Correlation

The correlation between CRDF and VSTM is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CRDF vs. VSTM - Dividend Comparison

Neither CRDF nor VSTM has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CRDF vs. VSTM - Drawdown Comparison

The maximum CRDF drawdown since its inception was -99.96%, roughly equal to the maximum VSTM drawdown of -98.96%. Use the drawdown chart below to compare losses from any high point for CRDF and VSTM.

Drawdown Indicators

	CRDF	VSTM	Difference
Max Drawdown Largest peak-to-trough decline	-99.96%	-98.96%	-1.00%
Max Drawdown (1Y) Largest decline over 1 year	-66.74%	-54.97%	-11.77%
Max Drawdown (5Y) Largest decline over 5 years	-90.44%	-96.22%	+5.78%
Max Drawdown (10Y) Largest decline over 10 years	-99.84%	-98.16%	-1.68%
Current Drawdown Current decline from peak	-99.92%	-97.49%	-2.43%
Average Drawdown Average peak-to-trough decline	-86.06%	-74.99%	-11.07%
Ulcer Index Depth and duration of drawdowns from previous peaks	42.77%	29.13%	+13.64%

Volatility

CRDF vs. VSTM - Volatility Comparison

The current volatility for Cardiff Oncology, Inc. (CRDF) is 16.29%, while Verastem, Inc. (VSTM) has a volatility of 20.91%. This indicates that CRDF experiences smaller price fluctuations and is considered to be less risky than VSTM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CRDF	VSTM	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.29%	20.91%	-4.62%
Volatility (6M) Calculated over the trailing 6-month period	63.44%	55.68%	+7.76%
Volatility (1Y) Calculated over the trailing 1-year period	83.87%	85.73%	-1.86%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	99.20%	105.90%	-6.70%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	105.89%	97.39%	+8.50%

Financials